GET DAILY SIGNALSCompugen Ltd. (CGEN): Analyst Targets Point to +136% Upside Potential
Key Takeaways
- The central $4.75 target is the arithmetic mean of four verified analyst price targets — $4.00, $4.00, $5.00 and $6.00 — not a single firm's forecast.
- Analyst targets range from $4.00 to $6.00, with major data providers citing a consensus average of roughly $4.60 to $5.00.
- At a recent price near $2.01, reaching $4.75 would require a gain of about 136%, a very large move.
- Key supports include the COM701 ovarian-cancer program, a cash runway into 2029, and collaborations with AstraZeneca and Gilead Sciences.
- Principal risks include binary clinical-trial outcomes, a thin commercial revenue base, and financing/dilution risk.
- For more detail, explore Major News, Today's Price Move, Forecast, and Earnings pages for CGEN.
- Readers can also explore Trending AI Robots for AI-driven trading ideas across the market.
Analyst Price Targets and Consensus View
Compugen Ltd. (CGEN), a clinical-stage cancer immunotherapy company headquartered in Holon, Israel, is covered by a small but clearly bullish group of analysts. Four current, attributable targets were reviewed: $4.00 from H.C. Wainwright (analyst Swayampakula Ramakanth, reiterated in October 2026), $4.00 from Stifel, $5.00 from Leerink Partners (which lowered its target from $13 in May 2026 while keeping an Outperform rating), and $6.00 from Lake Street Capital Markets (initiated in April 2026). The arithmetic mean of these four targets is $4.75, with a low-to-high range of $4.00 to $6.00.
Because the stock trades well below every target, no minimum-distance adjustment was needed. The overall rating skews strongly positive, with several sources describing the analyst consensus as "Strong Buy" or "Buy." The wide spread between the lowest and highest targets reflects genuine disagreement about how aggressively to value a company whose fortunes hinge on clinical data, not yet on product revenue. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
Current Market Position and Path Toward the Target
CGEN closed near $2.01 in early November 2026, within a 52-week range of roughly $1.43 to $3.24, giving the company a market capitalization of about $190 million. Reaching $4.75 would require an approximate 136% rise — a very large move that would first require the stock to reclaim and exceed its 52-week high.
The path is fundamentally data-driven. Compugen's lead asset, COM701, a potential first-in-class anti-PVRIG antibody, is being evaluated in the MAIA-ovarian adaptive platform trial, with interim median progression-free survival data expected in the first quarter of 2027. Positive data could materially re-rate the shares, while the company's AI/ML-powered Unigen discovery platform and partnered programs provide additional, longer-dated optionality.
What Could Support a Move Toward the Target
Several factors could support a re-rating. The company reported roughly $125.3 million in cash and investments as of mid-2026, extending its runway into 2029, which reduces near-term financing risk. Its partnerships — rilvegostomig with AstraZeneca and GS-0321 with Gilead Sciences — provide validation and potential milestone revenue. Revenue of $2.6 million in the second quarter of 2026 roughly doubled year over year, and the stock's computational-discovery positioning has attracted attention amid broader interest in AI-enabled biotechnology.
What Could Prevent the Target From Being Reached
The risks are substantial and largely binary. COM701's interim ovarian-cancer data could disappoint, and a clinical setback would likely compress the valuation sharply. Compugen remains a clinical-stage company with limited recurring revenue, and analyst targets span a wide range precisely because outcomes are uncertain. The company has also filed a $400 million mixed securities shelf, meaning future capital raises could dilute existing holders. A rotation away from speculative biotech during risk-off markets would add further pressure.
Technical Levels and Market Structure
Technically, the stock sits in the middle of its 52-week range. The $3.24 area represents the most significant resistance, as it marks the recent 52-week high; a decisive move above it would be required before the $4.75 target becomes a realistic zone of discussion. On the downside, the $1.43 52-week low and the $2.00 psychological level are the main support areas to watch.
Time Horizon and What Investors Should Monitor
Analyst price targets typically reflect a roughly 12-month research horizon, though the timeline can vary by firm and is not a guarantee. The most important near-term events are the third-quarter 2026 earnings report scheduled for November 9, 2026, subsequent analyst revisions, and the MAIA-ovarian interim data expected by the first quarter of 2027. Updates on partnered programs and any financing activity are also worth monitoring. From what I see, keeping an eye on these milestones will be key.
AI Daily Buy/Sell Signals
I have found Tickeron's AI Daily Buy/Sell Signals helpful for monitoring stocks like this. The tool uses artificial intelligence to track thousands of stocks and ETFs in real time, producing Buy, Sell, or Hold signals based on market conditions and technical factors. For a data-dependent name such as CGEN, it offers a way to stay on top of shifting trends alongside other research.
Final Assessment
The $4.75 central target, derived from four analyst price targets ranging from $4.00 to $6.00, implies a very large move of about 136% from the recent price near $2.01. Support rests on the COM701 data catalyst, a strong cash position, and high-profile partnerships, while the principal obstacles are binary clinical risk, limited commercial revenue, and potential dilution. Investors should focus on the upcoming earnings release, analyst revisions, and the MAIA-ovarian interim data as the clearest signposts for whether the stock can close the gap toward the target.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
I’m a trader and independent researcher. My interest lies at the intersection of financial markets, algorithms, and capital management. I develop data-driven tools and strategies and study algorithmic approaches to market analysis. I help turn complex market data into clear insights and practical systems. I believe technology should support, not replace, investment thinking
CGEN's RSI Oscillator ascends from oversold territory
The RSI Oscillator for CGEN moved out of oversold territory on October 20, 2026. This could be a sign that the stock is shifting from a downward trend to an upward trend. Traders may want to buy the stock or call options. The A.I.dvisor looked at 44 similar instances when the indicator left oversold territory. In 39 of the 44 cases the stock moved higher. This puts the odds of a move higher at 89%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. 51 of 66 cases where CGEN's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 77%.
The Moving Average Convergence Divergence (MACD) for CGEN just turned positive on October 28, 2026. Looking at past instances where CGEN's MACD turned positive, the stock continued to rise in 42 of 49 cases over the following month. The odds of a continued upward trend are 86%.
Following a +3.55% 3-day Advance, the price is estimated to grow further. Considering data from situations where CGEN advanced for three days, in 190 of 234 cases, the price rose further within the following month. The odds of a continued upward trend are 81%.
CGEN may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Bearish Trend Analysis
The Momentum Indicator moved below the 0 level on November 03, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on CGEN as a result. In 73 of 83 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 88%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where CGEN declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 88%.
The Aroon Indicator for CGEN entered a downward trend on November 03, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron SMR rating for this company is 20 (best 1 - 100 worst), indicating very strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Seasonality Score of 42 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron PE Growth Rating for this company is 56 (best 1 - 100 worst), pointing to average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Price Growth Rating for this company is 63 (best 1 - 100 worst), indicating steady price growth. CGEN’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Valuation Rating of 75 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (2.146) is normal, around the industry mean (3.051). P/E Ratio (5.289) is within average values for comparable stocks, (-0.872). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (125.677) among similar stocks. P/S Ratio (3.083) is also within normal values, averaging (439.647).
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. CGEN’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a maker of drug and diagnostics
Industry Biotechnology
Advertisement